Table 1: Summary of most recommended treatments options in GI tract MALT lymphomas.

Location

Frequency

HP infection

Treatment

Comments

Esophagus

< 1%

NEA

 

≥ 3 cm: SR

< 3cm: ER

Usually Cht or Rt is added [8]

Stomach

60%

EI

 

 

EI/NI

NI

 

L: HPE. If relapse or not respond: Rt (best results) [4] [9]  +/- Cht +/- Sg

 

D: Cht based on R

L and low grade: Rt (the best results)

Ab regimen should be based on epidemiology and resistances.  t(11;18)/API2-MALT1 is associated with resistance to Ab.[10]

No agreement about Rt in these cases

Usually 30-40 Gy [9]

Cht in study, at this date, best results with R + Bd/Cl/ Fl

Small bowel

30%    

Campylobacter jejuni

EI

 

NI

 

Ab régimen [11]

 

 

L: SR/ER

     Rt

D: Cht based on R or Cl

 

Tetracycline or metronidazole and ampicillin at least 6 months

 

FLT

 

Usually R-CHOP

In study: R + Cl/Fl

Large bowel

- Cecum and rectum

 

 

 

- Sigmoid colon

 

2.5%

 

NEA

 

 

 

 

NEA

 

 

L: SR/ER

D: Cht based on R

     Rt good responses

 

 

L: SR/ER

D: Cht based on R

 

 

Some cases responses at HPE (even negative). One case published of relapse after 1 year who received levofloxacin 14 days.

 

FLT [4]

Rt before resection to dismal the lesion is also an option

Usually R-CHOP +/- Rt [4]

R in monotherapy is being studied [4]

NEA: No Evidence of Association; EI: Evidence of Infection; NI: No Evidence of Infection; L: Localized; D: Disseminated; SR: Surgical Resection; ER: Endoscopic Resection S; Cht: Chemotherapy; Rt: Radiotherapy; Sg: Surgery; HP: Helycobacter pylori; HPE: HP Eradication; Ab: Antibiotics; FLT: First Line Treatment; HPE: Helicobacter pylori Eradication; R- CHOP: Rituximab Cyclophosphamide Hydroxydaunomycin Oncovin Prednisolone; R: Rituximab; Cl: Clorambucil; Bd: Bendamustine; Fl: Fludarabine.